Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Eye Diseases: early-phase trial registry
11 of 28 indexed Eye Diseases trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #577 of 28,707 conditions by registered trial count.
28 US clinical trials · 11 currently recruiting · #577 of 28,707 conditions by registered trial count
Eye Diseases: 28 US clinical trials tracked, 11 recruiting.
Eye Diseases is the subject of 28 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most active sponsor is National Eye Institute (NEI), running 4 of these trials.
Enrollment posture brief
Registry condition eye-diseases
OPEN 11 | RECR 39% | LATE 4 | EARLY 10 | RANK #577 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Primary Peritoneal Cancer (39% recruiting · 28 trials)
Eye Diseases lists 11 open slots (39% of 28 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Eye Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Eye Diseases recruits in line with its size-band peers.
11 of 28 indexed trials (39.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Eye Diseases trials is spread across many organizations.
National Eye Institute (NEI) accounts for 4 of 28 trials (14.3%). 21 distinct sponsors appear on at least one study for this condition label.
-
Most Eye Diseases trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 28 trials that report a genuine target (sentinel values excluded). 17 of those (60.7%) plan for fewer than 100 participants.
-
Eye Diseases splits between interventional and observational designs.
16 interventional and 12 observational studies make up this index (57.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
28 total, page 1 of 1
IRIS Registry: Intelligent Research in Sight Registry
American Academy of Ophthalmology
NCT02485847
Screening for Research Participants
National Eye Institute (NEI)
NCT00655096
Adaptive Optics Retinal Imaging
National Eye Institute (NEI)
NCT02317328
Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2
University of Michigan
NCT06934577
Assessment of the Ocular Microbiome in Health and Disease
Vanderbilt University Medical Center
NCT05414994
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT06112340
SGLT2 Inhibitors in Geographic Atrophy
Washington University School of Medicine
NCT07174687
Widefield Confocal Scanning Laser Ophthalmoscope Optimized for Pediatric and Neonatal Imaging
Duke University
NCT06177639
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
Southern College of Optometry
NCT07266948
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Laboratoires Thea
NCT06891443
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
PYC Therapeutics
NCT06455826
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
Columbia University
NCT04271709
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
Complement Therapeutics
NCT05797896
Rate of Progression in EYS Related Retinal Degeneration
Jaeb Center for Health Research
NCT04127006
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sling Therapeutics
NCT05276063
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ProQR Therapeutics
NCT03913143
Non-Interventional Long Term Follow-up Study of Participants Previously Enrolled in the RESTORE Study
Nanoscope Therapeutics
NCT06162585
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ProQR Therapeutics
NCT04123626
Phase 3 Safety Study for the Treatment of Presbyopia Subjects
LENZ Therapeutics
NCT05753189
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases
National Eye Institute (NEI)
NCT00076271
Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
National Eye Institute (NEI)
NCT00357071
Triton Agreement and Precision Study
Topcon Medical Systems
NCT03080714
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
Alcon Research
NCT00315640
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
LENZ Therapeutics
NCT05294328
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
Nanoscope Therapeutics
NCT04945772
Natural History Study of CEP290-Related Retinal Degeneration
Editas Medicine
NCT03396042
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
Pfizer
NCT01003691
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
Novartis Pharmaceuticals
NCT03954626
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Eye Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Eye Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Eye Diseases page
28 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Eye Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Eye Institute (NEI) sponsors the most Eye Diseases trials on record, review their full trial history before evaluating a specific study. See National Eye Institute (NEI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Eye Diseases condition card totals 28 registered trials; most-linked intervention Aceclidine+Brimonidine combination ophthalmic solution; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.